Cellectar Biosciences Advances Global Regulatory Strategy, Raises $12.7M, and Pursues Strategic Partnerships

Cellectar Biosciences Inc (CLRB) has made significant advancements in its global regulatory strategy for iapofecine I-131, receiving confirmation of eligibility to file for conditional marketing approval in the EU. The company has strengthened its balance sheet by raising approximately $12.7 million in recent financings and is actively pursuing strategic partnerships to expedite the commercialization of iapofecine I-131 and secure non-dilutive capital. However, CLRB reported a decrease in cash and cash equivalents, and faces significant financial requirements for the full patient enrollment of the phase 3 confirmatory study in the US.